Compare · ALHC vs ILMN
ALHC vs ILMN
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $23.91B, about 7.5x ALHC ($3.17B).
- Over the past year, ALHC is up 3.8% and ILMN is up 86.1% - ILMN leads by 82.3 points.
- ILMN has been more active in the news (22 items in the past 4 weeks vs 6 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Illumina Inc.
- Price
- $15.34-0.26%
- $158.13-2.55%
- Market cap
- $3.17B
- $23.91B
- 1M return
- -15.90%
- +14.02%
- 1Y return
- +3.79%
- +86.08%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ALHC
- President - MSO Kent Mark D. bought $197,627 worth of shares (14,848 units at $13.31) (SEC Form 4)
- SEC Form 3 filed by new insider Hochradel Shane J.
- Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report
- SEC Form 3 filed by new insider Kent Mark D.
- President Maroney Dawn Christine gifted 21,500 shares and sold $482,565 worth of shares (30,000 units at $16.09) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 977,313 units (SEC Form 4)
- Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Alignment Healthcare Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alignment Healthcare Inc.
- Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
- Chief Executive Officer Kao John E sold $5,032,850 worth of shares (298,000 units at $16.89) as part of a pre-agreed trading plan (SEC Form 4)
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits